Evidence map›Paper›PMID 25538133›Full record

ReviewExperimental biology and medicine (Maywood, N.J.)2015

WWOX: a fragile tumor suppressor.

Morgan S Schrock, Kay Huebner

Abstract readReview
In one paragraph

Review in Experimental biology and medicine (Maywood, N.J.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Frontiers in cell and developmental biology · 2020
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Immunohistochemical WWOX Expression and Association with Angiogenesis, p53 Expression, Cell Proliferation and Clinicopathological Parameters in Cervical Cancer.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2018
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Morgan S SchrockBiomedical Sciences Graduate Program, Ohio State University Wexner Medical Center, Columbus, Ohio 43210, USA Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, Ohio State University Wexner Medical Center, Columbus, Ohio 43210, USA.
Kay HuebnerDepartment of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, Ohio State University Wexner Medical Center, Columbus, Ohio 43210, USA kay.huebner@osumc.edu.
The Ohio State University Wexner Medical Center · US

Funding

MicroRNA profiles of TN breast cancer to define subgroups and targets for therapyU01CA154200 · NCI · OHIO STATE UNIVERSITY · PI HUEBNER, KAY · 2010 to 2014
$2.3M
Mouse Pathobiology: Models of Human DiseaseT32OD010429 · OD · OHIO STATE UNIVERSITY · PI NIEWIESK, STEFAN, OGLESBEE, MICHAEL J · 2012 to 2017
$1.3M
Wwox as a Critical Signal Mediator in Breast CancerR01CA120516 · NCI · OHIO STATE UNIVERSITY · PI HUEBNER, KAY · 2006 to 2013
$1.3M
NCI NIH HHS R01 CA120516NCI NIH HHS U01 CA154200NIH HHS 9T32 OD010429NIH HHS T32 OD010429
6 · The paper itself

Abstract

WWOX, the WW domain-containing oxidoreductase gene at chromosome region 16q23.3-q24.1, spanning chromosomal fragile site FRA16D, encodes the 46 kDa Wwox protein, a tumor suppressor that is lost or reduced in expression in a wide variety of cancers, including breast, prostate, ovarian, and lung. The function of Wwox as a tumor suppressor implies that it serves a function in the prevention of carcinogenesis. Indeed, in vitro studies show that Wwox protein interacts with many binding partners to regulate cellular apoptosis, proliferation, and/or maturation. It has been reported that newborn Wwox knockout mice exhibit nascent osteosarcomas while Wwox(+/-) mice exhibit increased incidence of spontaneous and induced tumors. Furthermore, absence or reduction of Wwox expression in mouse xenograft models results in increased tumorigenesis, which can be rescued by Wwox re-expression, though there is not universal agreement among investigators regarding the role of Wwox loss in these experimental models. Despite this proposed tumor suppressor function, the overlap of the human WWOX locus with FRA16D sensitizes the gene to protein-inactivating deletions caused by replication stress. The high frequency of deletions within the WWOX locus in cancers of various types, without the hallmark protein inactivation-associated mutations of "classical" tumor suppressors, has led to the proposal that WWOX deletions in cancers are passenger events that occur in early cancer progenitor cells due to fragility of the genetic locus, rather than driver events which provide the cancer cell a selective advantage. Recently, a proposed epigenetic cause of chromosomal fragility has suggested a novel mechanism for early fragile site instability and has implications regarding the involvement of tumor suppressor genes at chromosomal fragile sites in cancer. In this review, we provide an overview of the evidence for WWOX as a tumor suppressor gene and put this into the context of fragility associated with the FRA16D locus.

Indexed as

AnimalsCarcinogenesisChromosome Fragile SitesDisease Models, AnimalHumansMiceMutationOxidoreductasesTumor Suppressor ProteinsWW Domain-Containing OxidoreductaseOxidoreductasesTumor Suppressor ProteinsWW Domain-Containing OxidoreductaseWWOX protein, humanWwox protein, mouseFOR geneFRA16Dfragile sitesWOX1WWOX-human geneWwox- human/mouse proteinWwox- mouse gene

Identifiers

PMID25538133
PMCPMC4471953
OpenAlexW2019839182

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.